FDA advisory committee votes on whether the Pfizer-BioNTech COVID-19 vaccine should be authorized in 5 to 11 year olds; the Moderna vaccine elicits strong antibody responses in children; trial results shed light on booster dose efficacy; CDC panel recommends Shingrix for immunocompromised patients; a novel treatment is approved for macular edema associated with uveitis; and Pepaxto is withdrawn from the market following new study findings.